Press Release Archive

(BUSINESS WIRE)--84 percent of ex-smokers who consulted with their doctor or another healthcare professional during their final successful quit attempt believe that giving up would have been more difficult if they had tried to quit alone – according to the results of a new European survey announced today.(1) The survey, which investigated the attitudes of nearly 1,000 ex-smokers on smoking and smoking cessation, revealed that 74 percent

(BUSINESS WIRE)--Pfizer Inc today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) issued for dalbavancin HCl, Pfizer’s once-weekly two-dose antibiotic under FDA review for the treatment of adult patients with complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The FDA recently published a draft guidance

(BUSINESS WIRE)--Pfizer Inc announced today it has entered into an agreement to acquire CovX, a privately-held biotherapeutics company specializing in preclinical oncology and metabolic research and a developer of a biotherapeutics technology platform that will enhance Pfizer’s biologic portfolio. “The acquisition of CovX is a further step in Pfizer’s strategy to acquire and identify new product candidates

(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 32-cent first–quarter, 2008, dividend on the company’s common stock, payable March 4, 2008, to shareholders of record at the close of business on February 8, 2008. Pfizer increased the dividend by approximately 10 percent from 29 cents to 32 cents per share as part of the Company’s continued commitment to enhancing shareholder return

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced the commencement of its cash tender offer for all outstanding shares of common stock of Coley Pharmaceutical Group, Inc. (Nasdaq:COLY) for $8.00 per share. The tender offer is being made pursuant to an Offer to Purchase, dated November 30, 2007, and in connection with the Agreement and Plan of Merger, dated November 15, 2007, by and among Pfizer, Corvette Acquisition Corp., an indirect

(BUSINESS WIRE)--NEW YORK

(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) was more effective than simvastatin (20 mg–40 mg) in reducing the risk of multiple cardiovascular events in patients with a history of heart attacks in the Incremental Decreases through Aggressive Lipid Lowering (IDEAL) clinical trial. Cardiovascular events included heart attack, stroke, and cardiac revascularization

(BUSINESS WIRE)--Pfizer announced today that new data regarding the cardiovascular and kidney function effects of Lipitor® (atorvastatin calcium) Tablets will be presented next week at the Annual Scientific Sessions of the American Heart Association. SPARCL Trial A new post-hoc analysis (planned after the study completed) of the Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study looked

(BUSINESS WIRE)--Pfizer Inc said today that the Federal Patent Court in Munich, Germany has revoked the company’s patent covering atorvastatin calcium, the active ingredient in Lipitor. The patent at issue in the lawsuit (EP 409,281) expires in July 2010. The decision — which resulted from a patent challenge by generic manufacturers Ranbaxy Laboratories Limited and Basics GmbH — has no immediate commercial